Insulin access still “severely limited” in low income countries, report finds

Elisabeth Mahase writes about the Access to Medicine Foundation's report that examines pharmaceutical companies' strategies to overcome barriers to access to insulin, highlights areas where progress has been made and identifies opportunities for future action.

The article features responses to the report from Eli Lilly, Novo Nordisk and Sanofi, the main insulin manufacturers in the focus of the report.